首页> 外文期刊>Experimental and clinical transplantation >Epstein-Barr Viral Load Before a Liver Transplant in Children With Chronic Liver Disease
【24h】

Epstein-Barr Viral Load Before a Liver Transplant in Children With Chronic Liver Disease

机译:慢性肝病患儿肝移植前的爱泼斯坦-巴尔病毒载量

获取原文
           

摘要

Objectives: Many children with chronic liver disease require a liver transplant. These patients are prone to various infections, including Epstein-Barr virus infection. This study sought to measure the Epstein-Barr viral load by polymerase chain reaction before a liver transplant. Materials and Methods: This cross-sectional study was done at the Shiraz University of Medical Sciences, Shiraz, Iran, in 2011. All patients were aged younger than 18 years with chronic liver disease and were candidates for a liver transplant at the Shiraz Nemazee Hospital Organ Transplant Center. They had been investigated regarding their demographic characteristics, underlying disease, laboratory findings, and Epstein-Barr viral load by real-time TaqMan polymerase chain reaction. Results: Ninety-eight patients were studied and the mean age was 6.5 ± 5.9 years. Cryptogenic cirrhosis was the most-prevalent reason for liver transplant, and the death rate before a transplant was 15%. Among the study subjects, 6 had measurable Epstein-Barr viral load by polymerase chain reaction before the transplant, and 4 of them had considerably higher Epstein-Barr viral loads (more than 1000 copies/mL). Conclusions: With respect to the close prevalence of posttransplant lymphoproliferative disease (6%) and the high Epstein-Barr viral load in the patients before a transplant (4%), high pretransplant Epstein-Barr viral load can be considered a risk factor for posttransplant lymphoproliferative disorder.
机译:目的:许多患有慢性肝病的儿童需要进行肝移植。这些患者容易受到各种感染,包括爱泼斯坦-巴尔病毒感染。这项研究试图通过肝移植前的聚合酶链反应来测量爱泼斯坦-巴尔病毒载量。材料和方法:这项横断面研究于2011年在伊朗设拉子的设拉子医学大学进行。所有患者均年龄小于18岁且患有慢性肝病,并且都是在设拉子内马兹医院进行肝移植的候选人器官移植中心。通过实时TaqMan聚合酶链反应对他们的人口统计学特征,潜在疾病,实验室发现和Epstein-Barr病毒载量进行了调查。结果:研究了98例患者,平均年龄为6.5±5.9岁。隐源性肝硬化是肝移植的最普遍原因,移植前的死亡率为15%。在研究对象中,有6名在移植前通过聚合酶链反应具有可测量的Epstein-Barr病毒载量,其中4名具有较高的Epstein-Barr病毒载量(超过1000拷贝/ mL)。结论:关于移植后淋巴增生性疾病的近患病率(6%)和移植前患者的高爱泼斯坦-巴尔病毒载量(4%),移植前爱泼斯坦-巴尔病毒载量高可以认为是移植后的危险因素淋巴增生性疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号